Harvard Bioscience (HBIO) Income from Non-Controlling Interests (2013 - 2020)
Harvard Bioscience's (HBIO) quarterly Income from Non-Controlling Interests came in at $92000.0 in Q3 2020, up 324.39% year-on-year from $21678.2 in Q4 2019, and up 936.36% on a QoQ basis from -$11000.0 in Q2 2020.
Harvard Bioscience (HBIO) Income from Non-Controlling Interests (2013 - 2020) Analysis & Trends
Harvard Bioscience (HBIO) has 8 years of Income from Non-Controlling Interests data on file, last reported at $92000.0 in Q3 2020.
- On a quarterly basis, Income from Non-Controlling Interests rose 324.39% year-over-year to $92000.0 in Q3 2020; TTM through Sep 2020 was -$176000.0, a 65.62% increase from a year earlier, with the FY2018 full-year figure at $31000.0, up 520.0% from the prior year.
- Income from Non-Controlling Interests for Q3 2020 stood at $92000.0, up from -$11000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for HBIO reached as high as $155000.0 in Q2 2018 and fell as low as -$279000.0 in Q2 2019.
- Historically, Income from Non-Controlling Interests has averaged -$40750.0 across 5 years, with a median of -$11500.0 in 2016.
- Across the five-year window, Income from Non-Controlling Interests slumped 6450.0% in 2018 and soared 324.39% in 2020, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $11000.0 in 2016, then soared by 754.55% to $94000.0 in 2017, then tumbled by 95.74% to $4000.0 in 2018, then slumped by 1125.0% to -$41000.0 in 2019, then surged by 324.39% to $92000.0 in 2020.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were $92000.0 in Q3 2020, -$11000.0 in Q2 2020, and -$216000.0 in Q1 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.12 Bn | 120.90 Bn | 1.96 Bn | -18.70 Mn |
| 2 | Becton Dickinson | 44.89 Bn | 44.07 Bn | 2.15 Bn | - |
| 3 | Alcon | 33.06 Bn | 31.40 Bn | 1.53 Bn | - |
| 4 | Medline | 32.81 Bn | 30.58 Bn | 1.84 Bn | 110.00 Mn |
| 5 | Resmed | 29.44 Bn | 27.78 Bn | 890.98 Mn | - |
| 6 | West Pharmaceutical Services | 23.12 Bn | 22.68 Bn | 329.20 Mn | - |
| 7 | Solventum | 14.06 Bn | 13.50 Bn | 1.10 Bn | - |
| 8 | Cooper Companies | 13.87 Bn | 13.73 Bn | 735.40 Mn | - |
| 9 | Align Technology | 12.07 Bn | 11.01 Bn | 736.59 Mn | - |
| 10 | Harvard Bioscience | 27.33 Mn | 20.23 Mn | 12.24 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 92,000.00 |
| Jun 30, 2020 | -11,000.00 |
| Mar 31, 2020 | -216,000.00 |
| Sep 30, 2019 | -41,000.00 |
| Jun 30, 2019 | -279,000.00 |
| Mar 31, 2019 | -196,000.00 |
| Dec 31, 2018 | 4,000.00 |
| Sep 30, 2018 | 126,000.00 |
| Jun 30, 2018 | 155,000.00 |
| Mar 31, 2018 | -254,000.00 |
| Dec 31, 2017 | 94,000.00 |
| Jun 30, 2017 | -93,000.00 |
| Mar 31, 2017 | 4,000.00 |
| Sep 30, 2016 | 11,000.00 |
| Jun 30, 2016 | -12,000.00 |
| Mar 31, 2016 | -36,000.00 |
| Sep 30, 2015 | -39,000.00 |
| Jun 30, 2015 | -12,000.00 |
| Mar 31, 2015 | -59,000.00 |
| Sep 30, 2014 | 23,000.00 |